Treatment of Gastroenteropancreatic Neuroendocrine Tumors with 177Lu-DOTA-TATE: Experience of the Portuguese Institute of Oncology in Porto

Authors

  • Inês Lucena Sampaio Serviço de Medicina Nuclear. Instituto Português de Oncologia. Porto. Portugal.
  • Henrique Vara Luiz Serviço de Endocrinologia. Hospital Garcia de Orta. Almada. Portugal.
  • Liliana Sobral Violante Serviço de Medicina Nuclear. Instituto Português de Oncologia. Porto. Portugal.
  • Ana Paula Santos Serviço de Endocrinologia. Instituto Português de Oncologia. Porto. Portugal.
  • Luís Antunes Serviço de Epidemiologia. Instituto Português de Oncologia. Porto. Portugal.
  • Isabel Torres Serviço de Endocrinologia. Instituto Português de Oncologia. Porto. Portugal.
  • Cristina Sanches Serviço de Cirurgia Geral. Instituto Português de Oncologia do Porto. Portugal.
  • Isabel Azevedo Serviço de Oncologia. Instituto Português de Oncologia. Porto. Portugal.
  • Hugo Duarte Serviço de Medicina Nuclear. Instituto Português de Oncologia. Porto. Portugal.

DOI:

https://doi.org/10.20344/amp.7306

Keywords:

177Lu-DOTATATE Gastrointestinal Neoplasms, Neuroendocrine Tumors, Pancreatic Neoplasms, (177lutetium-DOTA(O) Tyr3)octreotate.

Abstract

Introduction: The purpose of this article is to report the experience of the Portuguese Institute of Oncology - Porto in the treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE, regarding the safety and efficacy of this treatment modality.
Material and Methods: A retrospective analysis of clinical reports of patients with gastroenteropancreatic neuroendocrine tumors undergoing treatment with 177Lu-DOTA-TATE between April 2011 and November 2013 was performed.
Results: Thirty six cases were reviewed and 30 completed all 3 cycles of 177Lu-DOTA-TATE (83.3%). In these patients it was registered: acute side effects in 8.9% of cycles; grade 3 CTCAE liver toxicity in 13.3% of patients (all with previous abnormal liver function); absence of significant renal or hematologic toxicity; symptomatic improvement in 71.4% of patients; median overall time to progression of 25.6 months; median overall survival from diagnosis of 121.7 months. Patients with higher expression of somatostatin receptors had longer progression-free survival and overall survival times (p < 0.05).
Discussion: Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE is an effective, safe and well-tolerated treatment, as evidenced in our study by the following findings: symptomatic improvement in most patients and increased time to disease progression and survival (especially in those with higher sstr expression), with acute and significant subacute/chronic side effects reported only in a minority of cases.
Conclusion: Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE is a promising treatment for patients with gastroenteropancreatic neuroendocrine tumors, with demonstrated benefits in terms of safety and efficacy.

Downloads

Download data is not yet available.

Published

2016-11-30

How to Cite

1.
Sampaio IL, Luiz HV, Violante LS, Santos AP, Antunes L, Torres I, Sanches C, Azevedo I, Duarte H. Treatment of Gastroenteropancreatic Neuroendocrine Tumors with 177Lu-DOTA-TATE: Experience of the Portuguese Institute of Oncology in Porto. Acta Med Port [Internet]. 2016 Nov. 30 [cited 2024 Mar. 29];29(11):726-33. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7306

Issue

Section

Original